[Federal Register Volume 65, Number 74 (Monday, April 17, 2000)]
[Notices]
[Pages 20471-20472]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-9444]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by contacting Uri Reichman, 
at the Office of Technology Transfer, National Institutes of Health, 
6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; 
telephone: 301/496-7736 ext. 240; fax: 301/402-0220; e-mail: 
<a href="/cdn-cgi/l/email-protection#6510175224250b0c0d4b020a13"><span class="__cf_email__" data-cfemail="0376713442436d6a6b2d646c75">[email protected]</span></a>. A signed Confidential Disclosure Agreement will

[[Page 20472]]

be required to receive copies of the patent applications.

Imaging With Positron-Emitting Taxanes as a Guide to Antitumor 
Therapy

Jerry M. Collins, Raymond W. Klecker, Lawrence Anderson (FDA)
Serial No. 60/155,061 filed 21 Sep 1999

    The present application discloses the use of positron-emitting 
compounds to label taxane type drugs. This invention also describes 
methods of synthesizing these taxane type compounds. Further, methods 
to guide treatment of solid tumors, with labeled taxanes, are also 
disclosed in the present application. Advantages of using this 
technology include: (1) Avoidance of exposing patients to toxic drugs 
that have no potential for benefit; (2) ability to rapidly determine 
whether a given tumor will be likely to respond to a particular drug; 
and (3) the ability to monitor the impact of various dosages, 
schedules, and modulators for delivery, in situ, at the actual tumor 
under treatment conditions.

Conjugate Vaccine for Neisseria Meningitidis

Xin-Xing Gu (NIDCD) and Chao-Ming Tsai (FDA)
Serial No. 60/148,021 filed 10 Aug 1999

    The invention discloses a vaccine which comprises 
lipooligosaccharide (LOS) isolated from N. meningitidis and conjugated 
to a carrier protein. The invention also discloses a method of making 
the acellular vaccine. The method consists of two main steps. In the 
first step the lipooligosaccharide (LOS), chosen so it does not contain 
the lacto-N-neotetraose human antigen (LNnT), is detoxified by a novel 
procedure which uses hydrazine to remove the O-linked fatty acids. In 
the second step, the detoxified LOS (dLOS) is covalently conjugated to 
a carrier protein such as Tetanus Toxoid (TT). The dLOS produced in 
step 1 is 10,000 fold less toxic than the parent LOS. The conjugate 
vaccine exhibited a high level of immunogenicity as evidenced by the 
high titer of IgG antibody to native LOS, obtained in mice and rabbits. 
The rabbit antisera produced by the conjugate vaccine of one 
N.meningitidis strain (strain 7880, A,L10) exhibited bactericidal 
activity and cross reactivity with heterologous N.meningitidis strains. 
A conjugate vaccine made in this method may be multivalent, composed of 
dLOSs from different strains and/or immunotypes of N. meningitidis and 
will thus protect against all types of N. meningitidis, including type 
B.
    A portion of this invention was disclosed in a poster by Tsai, Gu 
and Quakyi at the Fifth Conference of the International Endotoxin 
Society held in Santa Fe, New Mexico in September 12-15, 1998.

    Dated: April 7, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 00-9444 Filed 4-14-00; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>